UY25800A1 - Procedimiento para preparar composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina. - Google Patents
Procedimiento para preparar composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina.Info
- Publication number
- UY25800A1 UY25800A1 UY25800A UY25800A UY25800A1 UY 25800 A1 UY25800 A1 UY 25800A1 UY 25800 A UY25800 A UY 25800A UY 25800 A UY25800 A UY 25800A UY 25800 A1 UY25800 A1 UY 25800A1
- Authority
- UY
- Uruguay
- Prior art keywords
- insulin sensitizer
- pharmaceutical composition
- modified release
- procedure
- composition including
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un procedimiento para preparar una composición farmacéutica, que comprende formular el sensibilizador de insulina tiazolidinadiónico y el vehículo farmacéuticamente aceptable de modo que permita una liberación modificada del sensibilizador de insulina. Dicha composición es útil en el tratamiento de la diabetes mellitus de tipo 2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9824870.1A GB9824870D0 (en) | 1998-11-12 | 1998-11-12 | Novel composition and use |
GBGB9912189.9A GB9912189D0 (en) | 1999-05-25 | 1999-05-25 | Novel composition and use |
Publications (1)
Publication Number | Publication Date |
---|---|
UY25800A1 true UY25800A1 (es) | 2000-08-21 |
Family
ID=26314667
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY25798A UY25798A1 (es) | 1998-11-12 | 1999-11-12 | Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico. |
UY25800A UY25800A1 (es) | 1998-11-12 | 1999-11-15 | Procedimiento para preparar composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY25798A UY25798A1 (es) | 1998-11-12 | 1999-11-12 | Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico. |
Country Status (39)
Country | Link |
---|---|
EP (3) | EP1128827B1 (es) |
JP (1) | JP2002529505A (es) |
KR (2) | KR100732599B1 (es) |
CN (1) | CN1289081C (es) |
AP (2) | AP2008004490A0 (es) |
AR (2) | AR023699A1 (es) |
AT (1) | ATE382352T1 (es) |
AU (1) | AU768578B2 (es) |
BG (2) | BG65444B1 (es) |
BR (1) | BR9915215A (es) |
CA (1) | CA2350659C (es) |
CO (1) | CO5190673A1 (es) |
CY (1) | CY1107909T1 (es) |
CZ (1) | CZ20011628A3 (es) |
DE (1) | DE69937898T2 (es) |
DK (1) | DK1128827T3 (es) |
DZ (1) | DZ2937A1 (es) |
EA (3) | EA200702648A1 (es) |
EG (2) | EG24463A (es) |
ES (1) | ES2299269T3 (es) |
HK (1) | HK1040909B (es) |
HR (2) | HRP20010342B1 (es) |
HU (1) | HUP0104307A3 (es) |
ID (1) | ID29344A (es) |
IL (2) | IL143003A0 (es) |
MY (1) | MY135973A (es) |
NO (1) | NO20012351L (es) |
NZ (2) | NZ511611A (es) |
OA (1) | OA11676A (es) |
PE (1) | PE20001428A1 (es) |
PL (1) | PL198717B1 (es) |
PT (1) | PT1128827E (es) |
RS (1) | RS50208B (es) |
SI (1) | SI1128827T1 (es) |
SK (1) | SK286937B6 (es) |
TR (2) | TR200101337T2 (es) |
TW (2) | TWI257305B (es) |
UY (2) | UY25798A1 (es) |
WO (1) | WO2000028990A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6099862A (en) * | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
AR030920A1 (es) | 1999-11-16 | 2003-09-03 | Smithkline Beecham Plc | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones |
US20010026800A1 (en) * | 2000-01-07 | 2001-10-04 | Michael Jacob G. | Selective activation of a TH1 or TH2 lymphocyte regulated immune response |
CA2403670C (en) * | 2001-01-31 | 2010-02-09 | Rohm Gmbh & Co. Kg | Multiparticulate drug form comprising at least two differently coated pellet forms |
AU2002367154A1 (en) * | 2001-12-21 | 2003-07-15 | Smithkline Beecham Corporation | Dosing regimen for ppar-gamma activators |
MY139719A (en) * | 2002-02-12 | 2009-10-30 | Glaxo Group Ltd | Oral dosage form for controlled drug release |
CN100367960C (zh) * | 2002-07-11 | 2008-02-13 | 武田药品工业株式会社 | 包衣制剂的制备方法 |
US7018658B2 (en) * | 2002-11-14 | 2006-03-28 | Synthon Bv | Pharmaceutical pellets comprising tamsulosin |
CA2514879C (en) * | 2003-01-03 | 2014-09-16 | Shire Laboratories Inc. | Two or more enteric materials to regulate drug release |
CA2514539C (en) | 2003-01-29 | 2012-03-06 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
ES2241478B1 (es) * | 2004-02-13 | 2006-11-16 | Lacer S.A. | Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo. |
FI20060501L (fi) * | 2006-05-22 | 2007-11-23 | Biohit Oyj | Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa |
CN103945832B (zh) * | 2011-07-14 | 2017-03-29 | 能脑有限责任公司 | 用于脑能量分子延迟释放和持续释放的组合物,装置及方法 |
CA2936748C (en) | 2014-10-31 | 2017-08-08 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
JPS5697277A (en) | 1980-01-07 | 1981-08-05 | Takeda Chem Ind Ltd | Thiazolidine derivative |
JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
US4582839A (en) | 1984-03-21 | 1986-04-15 | Takeda Chemical Industries, Ltd. | 2,4-thiazolidinediones |
CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物,其制备方法和用途 |
DK173350B1 (da) | 1985-02-26 | 2000-08-07 | Sankyo Co | Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem |
JPH06779B2 (ja) | 1985-06-10 | 1994-01-05 | 武田薬品工業株式会社 | チアゾリジオン誘導体およびそれを含んでなる医薬組成物 |
US4812570A (en) | 1986-07-24 | 1989-03-14 | Takeda Chemical Industries, Ltd. | Method for producing thiazolidinedione derivatives |
SG59988A1 (en) * | 1987-09-04 | 1999-02-22 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
US4791125A (en) | 1987-12-02 | 1988-12-13 | Pfizer Inc. | Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents |
WO1989008651A1 (en) | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Hypoglycemic thiazolidinedione derivatives |
US5061717A (en) | 1988-03-08 | 1991-10-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
WO1991007107A1 (en) | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Oxazolidinedione hypoglycemic agents |
US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
AU650465B2 (en) | 1990-07-03 | 1994-06-23 | Yamanouchi Pharmaceutical Co., Ltd. | Bisheterocyclic compound |
DE69106714T2 (de) | 1990-08-23 | 1995-05-11 | Pfizer | Hypoglykämische hydroxyharnstoffderivate. |
JPH04210683A (ja) | 1990-12-06 | 1992-07-31 | Terumo Corp | チアゾリジン−2,4−ジオン誘導体およびこれを含有する糖尿病合併症治療薬 |
US5183823A (en) | 1991-04-11 | 1993-02-02 | Takeda Chemical Industries, Ltd. | Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents |
SK109993A3 (en) | 1991-04-11 | 1994-12-07 | Upjohn Co | Thiazolidinedione derivatives producing and use thereof |
US5502078A (en) * | 1991-05-28 | 1996-03-26 | Zeneca Limited | Chemical compounds |
TW222626B (es) | 1991-07-22 | 1994-04-21 | Pfizer | |
FR2680512B1 (fr) | 1991-08-20 | 1995-01-20 | Adir | Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
JPH05271204A (ja) | 1992-03-26 | 1993-10-19 | Japan Tobacco Inc | 新規なトリアジン誘導体 |
US5264451A (en) | 1992-04-07 | 1993-11-23 | American Home Products Corporation | Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones |
AU3959193A (en) | 1992-04-10 | 1993-11-18 | Smithkline Beecham Plc | Heterocyclic compounds and their use in the treatment of type II-diabetes |
WO1993022445A1 (en) | 1992-05-05 | 1993-11-11 | The Upjohn Company | A process for producing pioglitazone metabolite |
PL176885B1 (pl) | 1992-07-03 | 1999-08-31 | Smithkline Beecham Plc | Kompozycja farmaceutyczna |
US5326770A (en) * | 1992-07-17 | 1994-07-05 | The Du Pont Merck Pharmaceutical Company | Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals |
US5232945A (en) | 1992-07-20 | 1993-08-03 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives |
GB9218830D0 (en) | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
US5478852C1 (en) * | 1993-09-15 | 2001-03-13 | Sankyo Co | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus |
DE4432757A1 (de) * | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
JP3256841B2 (ja) * | 1996-06-27 | 2002-02-18 | 武田薬品工業株式会社 | ベンズアルデヒド化合物の製造法 |
US5952509A (en) * | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
GB9619757D0 (en) * | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
IL132032A0 (en) * | 1997-03-24 | 2001-03-19 | Galderma Res & Dev | Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus |
-
1999
- 1999-11-10 DZ DZ990237A patent/DZ2937A1/xx active
- 1999-11-10 AR ARP990105698A patent/AR023699A1/es unknown
- 1999-11-10 AR ARP990105699A patent/AR023700A1/es unknown
- 1999-11-11 EG EG142999A patent/EG24463A/xx active
- 1999-11-11 MY MYPI99004894A patent/MY135973A/en unknown
- 1999-11-11 CO CO99070989A patent/CO5190673A1/es not_active Application Discontinuation
- 1999-11-11 EG EG142899A patent/EG22344A/xx active
- 1999-11-12 PT PT99956029T patent/PT1128827E/pt unknown
- 1999-11-12 CZ CZ20011628A patent/CZ20011628A3/cs unknown
- 1999-11-12 AU AU12729/00A patent/AU768578B2/en not_active Ceased
- 1999-11-12 AT AT99956029T patent/ATE382352T1/de not_active IP Right Cessation
- 1999-11-12 BR BR9915215-0A patent/BR9915215A/pt not_active Application Discontinuation
- 1999-11-12 PE PE1999001147A patent/PE20001428A1/es not_active Application Discontinuation
- 1999-11-12 PL PL348153A patent/PL198717B1/pl not_active IP Right Cessation
- 1999-11-12 OA OA1200100116A patent/OA11676A/en unknown
- 1999-11-12 KR KR1020017005949A patent/KR100732599B1/ko not_active IP Right Cessation
- 1999-11-12 RS YU36401A patent/RS50208B/sr unknown
- 1999-11-12 EP EP99956029A patent/EP1128827B1/en not_active Expired - Lifetime
- 1999-11-12 DK DK99956029T patent/DK1128827T3/da active
- 1999-11-12 EA EA200702648A patent/EA200702648A1/ru unknown
- 1999-11-12 WO PCT/EP1999/009031 patent/WO2000028990A1/en active Application Filing
- 1999-11-12 NZ NZ511611A patent/NZ511611A/en not_active IP Right Cessation
- 1999-11-12 NZ NZ526440A patent/NZ526440A/en not_active IP Right Cessation
- 1999-11-12 ES ES99956029T patent/ES2299269T3/es not_active Expired - Lifetime
- 1999-11-12 AP AP2008004490A patent/AP2008004490A0/xx unknown
- 1999-11-12 SI SI9931001T patent/SI1128827T1/sl unknown
- 1999-11-12 DE DE69937898T patent/DE69937898T2/de not_active Expired - Lifetime
- 1999-11-12 CN CNB998154946A patent/CN1289081C/zh not_active Expired - Fee Related
- 1999-11-12 SK SK643-2001A patent/SK286937B6/sk not_active IP Right Cessation
- 1999-11-12 EA EA200601144A patent/EA200601144A1/ru unknown
- 1999-11-12 EP EP07150269A patent/EP1917962A1/en not_active Withdrawn
- 1999-11-12 HU HU0104307A patent/HUP0104307A3/hu unknown
- 1999-11-12 EA EA200100540A patent/EA007608B1/ru not_active IP Right Cessation
- 1999-11-12 TR TR2001/01337T patent/TR200101337T2/xx unknown
- 1999-11-12 IL IL14300399A patent/IL143003A0/xx unknown
- 1999-11-12 JP JP2000582037A patent/JP2002529505A/ja active Pending
- 1999-11-12 AP APAP/P/2001/002135A patent/AP1901A/en active
- 1999-11-12 CA CA002350659A patent/CA2350659C/en not_active Expired - Fee Related
- 1999-11-12 TR TR2005/03846T patent/TR200503846T2/xx unknown
- 1999-11-12 EP EP07105991A patent/EP1815855A1/en not_active Withdrawn
- 1999-11-12 KR KR1020067017464A patent/KR20060097140A/ko not_active Application Discontinuation
- 1999-11-12 UY UY25798A patent/UY25798A1/es not_active Application Discontinuation
- 1999-11-12 ID IDW00200101047A patent/ID29344A/id unknown
- 1999-11-15 UY UY25800A patent/UY25800A1/es not_active Application Discontinuation
- 1999-12-24 TW TW093132308A patent/TWI257305B/zh active
- 1999-12-24 TW TW088122852A patent/TWI246920B/zh not_active IP Right Cessation
-
2001
- 2001-05-11 HR HR20010342A patent/HRP20010342B1/xx not_active IP Right Cessation
- 2001-05-11 NO NO20012351A patent/NO20012351L/no not_active Application Discontinuation
- 2001-06-07 BG BG105570A patent/BG65444B1/bg unknown
- 2001-06-07 BG BG109893A patent/BG109893A/bg unknown
-
2002
- 2002-02-08 HK HK02101021.9A patent/HK1040909B/zh not_active IP Right Cessation
-
2007
- 2007-06-14 IL IL183972A patent/IL183972A0/en unknown
-
2008
- 2008-03-17 HR HR20080117A patent/HRP20080117A2/xx not_active Application Discontinuation
- 2008-03-19 CY CY20081100310T patent/CY1107909T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY25800A1 (es) | Procedimiento para preparar composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina. | |
UY25799A1 (es) | Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina y otro agente antidiabético. | |
AR017979A1 (es) | Formulaciones farmaceuticas de epotilonas, metodo para su preparacion y el uso de los mismos para la manufactura de un medicamento | |
AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
AR025959A1 (es) | DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
ES2160577T3 (es) | Nuevos esteres de aminoalcoholes biciclicos y triciclicos, su preparacion y su utilizacion en medicamentos. | |
AR032465A1 (es) | Derivados anticonvulsivos utiles para la preparacion de un medicamento para prevenir el desarrollo de la diabetes mellitus de tipo ii y del sindrome x | |
BR0113643A (pt) | Compostos de guanidinobenzamidas como agonistas de mc4-r e seus usos | |
CO5280073A1 (es) | Composiciones | |
CL2009001899A1 (es) | Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01). | |
AR024998A1 (es) | Nuevos retinoides para el tratamiento del enfisema | |
AR006401A1 (es) | Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos. | |
MY135920A (en) | New phenalkyloxy-phenyl derivatives | |
CO4940454A1 (es) | Nuevo metodo de tratamiento | |
AR019724A2 (es) | Composicion farmaceutica util para el tratamiento de diabetes mellitus y condiciones asociadas | |
AR008025A1 (es) | Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina | |
MY138246A (en) | Treatment of diabetes with thiazolidione and sulphonylurea. | |
UY25801A1 (es) | Procedimiento para preparar composiciones para el tratamiento de diabetes. | |
AR013352A1 (es) | Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica. | |
ES2188232T3 (es) | Uso de cetirizina para impedir la aparicion del asma. | |
AR127064A1 (es) | Prodroga de derivados de pirrolidona como activador de glucoquinasa | |
WO2001047509A3 (en) | Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions | |
AR028699A1 (es) | Nueva formulacion | |
ECSP993216A (es) | Nueva composicion y uso ii | |
ECSP982593A (es) | Nuevo metodo de tratamiento vi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RDES | Application refused |
Effective date: 20090302 |